CN110177805B - 抗体构建体 - Google Patents

抗体构建体 Download PDF

Info

Publication number
CN110177805B
CN110177805B CN201780078920.7A CN201780078920A CN110177805B CN 110177805 B CN110177805 B CN 110177805B CN 201780078920 A CN201780078920 A CN 201780078920A CN 110177805 B CN110177805 B CN 110177805B
Authority
CN
China
Prior art keywords
domain
amino acid
acid sequence
antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780078920.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110177805A (zh
Inventor
L·贝利
B·格拉泽
李曲飞
R·格林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invenra Inc
Original Assignee
Invenra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invenra Inc filed Critical Invenra Inc
Priority to CN202410343134.7A priority Critical patent/CN118359705A/zh
Priority to CN202410332902.9A priority patent/CN118359704A/zh
Publication of CN110177805A publication Critical patent/CN110177805A/zh
Application granted granted Critical
Publication of CN110177805B publication Critical patent/CN110177805B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201780078920.7A 2016-10-19 2017-10-18 抗体构建体 Active CN110177805B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410343134.7A CN118359705A (zh) 2016-10-19 2017-10-18 抗体构建体
CN202410332902.9A CN118359704A (zh) 2016-10-19 2017-10-18 抗体构建体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662410054P 2016-10-19 2016-10-19
US62/410,054 2016-10-19
US201762549894P 2017-08-24 2017-08-24
US62/549,894 2017-08-24
US201762555498P 2017-09-07 2017-09-07
US62/555,498 2017-09-07
PCT/US2017/057268 WO2018075692A2 (en) 2016-10-19 2017-10-18 Antibody constructs

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410332902.9A Division CN118359704A (zh) 2016-10-19 2017-10-18 抗体构建体
CN202410343134.7A Division CN118359705A (zh) 2016-10-19 2017-10-18 抗体构建体

Publications (2)

Publication Number Publication Date
CN110177805A CN110177805A (zh) 2019-08-27
CN110177805B true CN110177805B (zh) 2024-04-02

Family

ID=60452719

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201780078920.7A Active CN110177805B (zh) 2016-10-19 2017-10-18 抗体构建体
CN202410332902.9A Pending CN118359704A (zh) 2016-10-19 2017-10-18 抗体构建体
CN202410343134.7A Pending CN118359705A (zh) 2016-10-19 2017-10-18 抗体构建体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410332902.9A Pending CN118359704A (zh) 2016-10-19 2017-10-18 抗体构建体
CN202410343134.7A Pending CN118359705A (zh) 2016-10-19 2017-10-18 抗体构建体

Country Status (15)

Country Link
US (2) US20180118811A1 (https=)
EP (2) EP3529269B1 (https=)
JP (2) JP7261158B2 (https=)
KR (3) KR20250044934A (https=)
CN (3) CN110177805B (https=)
AU (1) AU2017345454B2 (https=)
CA (1) CA3041254A1 (https=)
DK (1) DK3529269T3 (https=)
ES (1) ES3063689T3 (https=)
FI (1) FI3529269T3 (https=)
IL (1) IL266143B1 (https=)
LT (1) LT3529269T (https=)
MX (1) MX421186B (https=)
PT (1) PT3529269T (https=)
WO (1) WO2018075692A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
CN110177805B (zh) * 2016-10-19 2024-04-02 英温拉公司 抗体构建体
WO2019183406A1 (en) * 2018-03-21 2019-09-26 Invenra Inc. Multispecific antibody purification with ch1 resin
MA52212A (fr) 2018-03-30 2021-02-17 Merus Nv Anticorps multivalent
US20210163594A1 (en) * 2018-04-17 2021-06-03 Invenra Inc. Binding molecules
SG11202010235QA (en) 2018-04-18 2020-11-27 Exelixis Inc Anti-ror antibody constructs
EP3825333A4 (en) * 2018-07-06 2022-04-06 Abmax Biopharmaceuticals LOW FUNCTIONALITY ADCC/CDC MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE
WO2020028269A2 (en) * 2018-07-30 2020-02-06 Invenra Inc. Multispecific treg binding molecules
JP7596263B2 (ja) * 2018-10-10 2024-12-09 ザイムワークス ビーシー インコーポレイテッド ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
AU2019412561A1 (en) 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
EP4077374A4 (en) * 2019-12-20 2023-12-27 Kisoji Biotechnology Inc. POLYPEPTIDES, PROTEIN COMPLEXES AND METHODS FOR PRODUCING THE SAME
AU2021224883A1 (en) * 2020-02-20 2022-09-29 Invenra Inc. Bispecific GD2 and B7H2 binding molecules and methods of use
CA3207821A1 (en) * 2020-12-10 2022-06-16 Invenra Inc. Orthogonal mutations for heterodimerization
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
TW202506726A (zh) * 2023-04-07 2025-02-16 美商麥迪紐有限責任公司 雙特異性工程化抗體
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103857700A (zh) * 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体
CN104520319A (zh) * 2012-04-20 2015-04-15 莫鲁斯有限公司 用于产生免疫球蛋白样分子的方法和手段
WO2016087650A1 (en) * 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905551D0 (en) * 1989-03-10 1989-04-19 Unilever Plc Detergent compositions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
EP1928912A4 (en) 2005-09-07 2010-02-24 Medimmune Inc EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
AR074584A1 (es) 2008-12-10 2011-01-26 Mersana Therapeutics Inc Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables
AU2010254013A1 (en) 2009-05-28 2011-11-24 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
JP5830085B2 (ja) 2011-03-10 2015-12-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｏａｔｐ１ｂ１の輸送活性を促進又は阻害する化合物をスクリーニングするための方法、及びｏａｔｐ１ｂ１発現量を測定するための方法
WO2012171020A1 (en) 2011-06-10 2012-12-13 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
WO2013173337A2 (en) 2012-05-15 2013-11-21 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
CN104768578A (zh) 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
WO2014160360A1 (en) 2013-03-14 2014-10-02 Mersana Therapeutics Inc. Tubulysin compounds and conjugates thereof
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
KR102442906B1 (ko) 2013-12-19 2022-09-14 씨젠 인크. 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
CA2937753A1 (en) 2014-02-17 2015-08-20 Seattle Genetics, Inc. Hydrophilic antibody-drug conjugates
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP2017512814A (ja) 2014-04-07 2017-05-25 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤
US9808528B2 (en) 2014-06-18 2017-11-07 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
TWI551060B (zh) * 2014-09-24 2016-09-21 衡宇科技股份有限公司 Ｂｃｈ解碼方法及其解碼器
WO2016180941A1 (en) 2015-05-13 2016-11-17 Sanofi Liquid compositions for anti-cd19 antibody-drug conjugates
EP3325482B1 (en) 2015-07-21 2020-06-24 ImmunoGen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
GB2544086B (en) 2015-11-05 2021-04-28 Povey David Drip catcher for a stemmed drinking vessel
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
JP7137474B2 (ja) 2016-03-15 2022-09-14 メルサナ セラピューティクス，インコーポレイティド ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
EP3241531A1 (en) * 2016-05-04 2017-11-08 noonee AG Leg unit for a wearable sitting posture assisting device
CN110177805B (zh) * 2016-10-19 2024-04-02 英温拉公司 抗体构建体
US20210163594A1 (en) * 2018-04-17 2021-06-03 Invenra Inc. Binding molecules
CN112384243A (zh) * 2018-04-17 2021-02-19 英温拉公司 三价三特异性抗体构建体
SG11202010235QA (en) * 2018-04-18 2020-11-27 Exelixis Inc Anti-ror antibody constructs
WO2020028269A2 (en) * 2018-07-30 2020-02-06 Invenra Inc. Multispecific treg binding molecules
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103857700A (zh) * 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体
CN104520319A (zh) * 2012-04-20 2015-04-15 莫鲁斯有限公司 用于产生免疫球蛋白样分子的方法和手段
WO2016087650A1 (en) * 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody

Also Published As

Publication number Publication date
MX421186B (es) 2025-02-10
AU2017345454B2 (en) 2024-10-31
CA3041254A1 (en) 2018-04-26
KR20240000650A (ko) 2024-01-02
CN118359705A (zh) 2024-07-19
WO2018075692A2 (en) 2018-04-26
IL266143A (en) 2019-06-30
IL266143B1 (en) 2026-04-01
MX2019004690A (es) 2019-09-27
KR102617264B1 (ko) 2023-12-29
JP2022176374A (ja) 2022-11-25
AU2017345454A1 (en) 2019-05-30
KR20250044934A (ko) 2025-04-01
EP3529269A2 (en) 2019-08-28
LT3529269T (lt) 2026-03-25
EP4729535A2 (en) 2026-04-22
ES3063689T3 (en) 2026-04-20
JP7261158B2 (ja) 2023-04-19
WO2018075692A3 (en) 2019-04-04
EP3529269B1 (en) 2025-11-26
FI3529269T3 (fi) 2026-02-24
CN110177805A (zh) 2019-08-27
KR20190092380A (ko) 2019-08-07
JP7591015B2 (ja) 2024-11-27
US20240043502A1 (en) 2024-02-08
PT3529269T (pt) 2026-03-03
DK3529269T3 (da) 2026-02-23
NZ752832A (en) 2025-06-27
US20180118811A1 (en) 2018-05-03
JP2019534277A (ja) 2019-11-28
CN118359704A (zh) 2024-07-19

Similar Documents

Publication Publication Date Title
CN110177805B (zh) 抗体构建体
US20240392002A1 (en) Anti-ror antibody constructs
US20250026861A1 (en) Trivalent trispecific antibody constructs
US20220213225A1 (en) Multispecific treg binding molecules
US20210163594A1 (en) Binding molecules
WO2019183406A1 (en) Multispecific antibody purification with ch1 resin
AU2026202585A1 (en) Anti-ror antibody constructs
EA048615B1 (ru) Конструкции антител к ror

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20380203

TG01 Patent term adjustment